Cue Biopharma, Inc.

As of August 8, 2023, Cue Biopharma, Inc. is considered overvalued and risky due to its high Price to Book Value of 7.34 and negative EV to EBIT and EV to EBITDA ratios, significantly underperforming its peers and the S&P 500 with a year-to-date return of -33.02%.

As of August 8, 2023, Cue Biopharma, Inc. is considered overvalued and risky due to concerning financial ratios and a year-to-date stock decline of 39.91%, significantly underperforming the S&P 500's 2.44% gain.

As of June 20, 2025, the market trend is mildly bearish due to bearish signals from the weekly MACD and Bollinger Bands, despite some mildly bullish indicators on the monthly charts, suggesting caution overall.

As of March 2022, the management team of Cue Biopharma, Inc. includes Dr. Frank Morich (Independent Chairman), Mr. Daniel Passeri (CEO and Director), and several Independent Directors: Ms. Tamar Howson, Mr. Frederick Driscoll, Dr. Aaron Fletcher, Dr. Cameron Gray, and Dr. Peter Kiener. They oversee the company's strategic direction and operations.

Cue Biopharma, Inc. is a development-stage immunotherapy company focused on creating biologics to target T cell subsets for cancer and autoimmune disease treatments. As of March 2025, it has a market cap of $43.71 million, with no net sales and a net loss of $12 million.

As of Jun 18, Cue Biopharma, Inc. has a market capitalization of 43.71 million and reported net sales of 8.00 million with a net profit of -40.59 million over the latest four quarters.